All canine diagnoses

Your dog was diagnosed with Thyroid Carcinoma. ~1-4% of all canine tumours. ~90% of thyroid tumours in dogs are malignant (unlike cats where ~90% are benign). Most are non-functional (euthyroid). Mobile tumours have much better surgical prognosis than fixed/invasive. Compare 4 treatment options for dogs including Thyroidectomy (Mobile Tumours), High-Dose Radioactive Iodine (I-131), External Beam Radiation Therapy (Fixed Tumours) — with survival times, costs, and what to expect during treatment.

🐕

Thyroid Carcinoma

Mobile vs Fixed/Invasive

BreedsBeagleGolden RetrieverSiberian HuskyBoxerMedium-large breeds generally
canine

Epithelial

About This Cancer

Thyroid carcinoma is a cancer of the thyroid gland, an endocrine organ consisting of two lobes situated on either side of the windpipe in the neck, which regulates metabolism. In dogs, unlike in cats, the vast majority (approximately 90%) of thyroid tumours are malignant. However, most canine thyroid carcinomas are non-functional, meaning they do not produce excess thyroid hormones and the dog remains euthyroid (normal hormone levels). A key prognostic distinction is whether the tumour is freely mobile under the skin or fixed to surrounding tissues: mobile tumours are typically well-encapsulated and can be completely removed surgically with an excellent prognosis, while fixed, invasive tumours have already grown into surrounding structures and are much more challenging to treat. Beagles, Golden Retrievers, and Siberian Huskies appear to be at somewhat increased risk.

Clinical staging for canine thyroid carcinoma

Primarily classified by mobility (mobile vs fixed) which dictates treatment approach

Stage Mobile, unilateralFreely movable mass, one thyroid lobe — best surgical candidate
Stage Mobile, bilateralBoth thyroid lobes affected — bilateral thyroidectomy possible with thyroid supplementation
Stage Fixed/invasiveAdherent to surrounding structures (trachea, vessels) — surgery often not feasible as primary
Stage MetastaticDistant metastasis present (pulmonary in 35% at diagnosis)
Prognostic Factors(4)
Mobility (mobile vs fixed)Mobile: MST ~3 years with surgery. Fixed: MST 6-12 months without radiation. Strongest clinical prognostic factor.(Campos et al., 2014)
Tumour volumeLarger tumours have worse prognosis. Volume predicts response to I-131 and radiation.
Iodine uptake on scintigraphyIodine-avid tumours are candidates for I-131 therapy. Non-avid tumours require alternative approaches.
Bilateral involvementBilateral disease requires lifelong thyroid supplementation post-thyroidectomy but is not necessarily worse prognosis if completely excised.
Minimum Workup(8 steps)
1Cervical palpation (mobile vs fixed — critical treatment decision point)
2Cervical ultrasound (tumour dimensions, vascular invasion assessment)
3CT scan of neck and thorax (surgical planning, assess local invasion)
4Thyroid panel (T4, fT4 — most are euthyroid; hypothyroid with bilateral involvement)
5Thoracic radiographs (3-view) for pulmonary metastasis (35% have lung mets at diagnosis)
6Regional lymph node assessment (retropharyngeal, cervical)
7FNA of mass (if safe — avoid if highly vascular on US)
8Thyroid scintigraphy (99mTc pertechnetate) if I-131 therapy considered

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Thyroidectomy (Mobile Tumours)
~30 mo (20–48)
High-Dose Radioactive Iodine (I-131)
~19 mo (12–34)
External Beam Radiation Therapy (Fixed Tumours)
~24 mo (18–36)
Toceranib (Palladia) for Unresectable/Metastatic
~12 mo (6–18)
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.